Callyope announced the recent funding of €2.2 million (approx. $2.4 million) co-led by 360 Capital and Bpifrance Digital Venture, with participation from No Label Ventures and other angel investors.
Callyope develops speech-based remote patient monitoring solutions that can assist caretakers in assessing the efficacy of their treatments and preventing relapses to avoid hospitalization.
When it comes to mental health problems like schizophrenia, bipolar disorder, and other mental disorders, 1 in 2 patients is re-hospitalized within 12 months. Bipolar disorders can go undiagnosed even after some years of the onset of symptoms, and many patients take years to find the right antidepressant treatments. All these problems can be resolved if the psychiatrist can monitor their patients from time to time, even after the treatment, so that they can predict the symptoms and adjust the treatments to prevent relapses and rehospitalization.
Callyope is solving this problem with its speech-based remote patient monitoring solution, where patients perform a 1-minute voice test on a smartphone, either in-clinic or at home. With that voice test, Callyope’s technology analyzes the patient’s speech to predict a psychiatric clinical score, assess fatigue, and estimate cognition deficits.
The company’s co-founders are Martin Denais (CEO), Rachid Riad (CSO/CTO), and Xuan-Nga Cao (COO), and it is headquartered in Saint-Cloud, France.